Search research articles
Contact Us
Filters
Showing results (91-100 of 127) with videos related to
Page
of 13
Sort By:
Kidney International Reports
|
March 8, 2022
The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
Michele Provenzano, Niels Jongs, Priya Vart, et al.
Clinical Kidney Journal
|
April 3, 2023
Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe-lessons for the future
Marlies Noordzij, Björn Meijers, Ron T Gansevoort, et al.
International Journal of Cardiology
|
March 12, 2021
Vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease is dominated by vasospasm
Regina E Konst, Peter Damman, Dario Pellegrini, et al.
NEJM Evidence
|
February 6, 2024
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
Akihiko Koshino, Meir Schechter, Glenn M Chertow, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
January 17, 2023
Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database
Alferso C Abrahams, Marlies Noordzij, Eric Goffin, et al.
Journal of the American Society of Nephrology : JASN
|
July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Glenn M Chertow, Priya Vart, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 5, 2021
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure
Maria Jose Soler, Marlies Noordzij, Daniel Abramowicz, et al.
Diabetes Care
|
June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Frederik Persson, Peter Rossing, Priya Vart, et al.
Diabetes, Obesity & Metabolism
|
January 19, 2021
Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes
Namam Ali, Anna W M Janssen, Martin Jaeger, et al.
The Lancet. Planetary Health
|
April 5, 2024
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial
Zhiyan Zhang, Hiddo J L Heerspink, Glenn M Chertow, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 127) with videos related to
Sort By:
Page
of 13
Kidney International Reports
|
March 8, 2022
The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
Michele Provenzano, Niels Jongs, Priya Vart, et al.
Clinical Kidney Journal
|
April 3, 2023
Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe-lessons for the future
Marlies Noordzij, Björn Meijers, Ron T Gansevoort, et al.
International Journal of Cardiology
|
March 12, 2021
Vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease is dominated by vasospasm
Regina E Konst, Peter Damman, Dario Pellegrini, et al.
NEJM Evidence
|
February 6, 2024
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
Akihiko Koshino, Meir Schechter, Glenn M Chertow, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
January 17, 2023
Outcomes of COVID-19 in peritoneal dialysis patients: A report by the European Renal Association COVID-19 Database
Alferso C Abrahams, Marlies Noordzij, Eric Goffin, et al.
Journal of the American Society of Nephrology : JASN
|
July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Glenn M Chertow, Priya Vart, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 5, 2021
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure
Maria Jose Soler, Marlies Noordzij, Daniel Abramowicz, et al.
Diabetes Care
|
June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Frederik Persson, Peter Rossing, Priya Vart, et al.
Diabetes, Obesity & Metabolism
|
January 19, 2021
Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes
Namam Ali, Anna W M Janssen, Martin Jaeger, et al.
The Lancet. Planetary Health
|
April 5, 2024
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial
Zhiyan Zhang, Hiddo J L Heerspink, Glenn M Chertow, et al.
Page
of 13